scholarly journals A New Differential Diagnosis: Synthetic Cannabinoid-Associated Gross Hematuria

2019 ◽  
Vol 2019 ◽  
pp. 1-3 ◽  
Author(s):  
Osamah Hasan ◽  
Ankit A. Patel ◽  
James J. Siegert

Recreational use of synthetic cannabinoids (SCs), also known as “K2” or “Spice,” is becoming a major public-health concern due to their potential for abuse and harmful consequences. New substances are constantly being added to the content of SCs. The dearth of information on these newly added contents as they are introduced into the black market hinders risk assessments of these compounds. We report a highly unusual case of gross hematuria in a 28-year-old male patient after SC use. He was found to have a supratherapeutic INR with no history of prior anticoagulation. His hematuria resolved after four units of fresh-frozen plasma were administered. We include a literature review of the clinical effects of SCs and their possible mechanism of gross hematuria and management.

Author(s):  
Hortensia De la Corte-Rodriguez ◽  
E. Carlos Rodriguez-Merchan ◽  
M. Teresa Alvarez-Roman ◽  
Monica Martin-Salces ◽  
Victor Jimenez-Yuste

Background: It is important to discard those practices that do not add value. As a result, several initiatives have emerged. All of them try to improve patient safety and the use of health resources. Purpose: To present a compendium of "do not do recommendations" in the context of hemophilia. Methods: A review of the literature and current clinical guidelines has been made, based on the best evidence available to date. Results: The following 13 recommendations stand out: 1) Do not delay the administration of factor after trauma; 2) do not use fresh frozen plasma or cryoprecipitate; 3) do not use desmopressin in case of hematuria; 4) do not change the product in the first 50 prophylaxis exposures; 5) do not interrupt immunotolerance; 6) do not administer aspirin or NSAIDs; 7) do not administer intramuscular injections; 8) do not do routine radiographs of the joint in case of acute hemarthrosis; 9) Do not apply closed casts for fractures; 10) do not discourage the performance of physical activities; 11) do not deny surgery to a patient with an inhibitor; 12) do not perform instrumental deliveries in fetuses with hemophilia; 13) do not use factor IX (FIX) in patients with hemophilia B with inhibitor and a history of anaphylaxis after administration of FIX. Conclusions: The information mentioned previously can be useful in the management of hemophilia, from different levels of care. As far as we know, this is the first initiative of this type regarding hemophilia.


Blood ◽  
1992 ◽  
Vol 79 (3) ◽  
pp. 826-831 ◽  
Author(s):  
B Horowitz ◽  
R Bonomo ◽  
AM Prince ◽  
SN Chin ◽  
B Brotman ◽  
...  

Abstract Fresh frozen plasma (FFP) is prepared in blood banks world-wide as a by- product of red blood cell concentrate preparation. Appropriate clinical use is for coagulation factor disorders where appropriate concentrates are unavailable and when multiple coagulation factor deficits occur such as in surgery. Viral safety depends on donor selection and screening; thus, there continues to be a small but defined risk of viral transmission comparable with that exhibited by whole blood. We have prepared a virus sterilized FFP (S/D-FFP) by treatment of FFP with 1% tri(n-butyl)phosphate (TNBP) and 1% Triton X-100 at 30 degrees C for 4 hours. Added reagents are removed by extraction with soybean oil and chromatography on insolubilized C18 resin. Treatment results in the rapid and complete inactivation of greater than or equal to 10(7.5) infectious doses (ID50) of vesicular stomatitis virus (VSV) and greater than or equal to 10(6.9) ID50 of sindbis virus (used as marker viruses), greater than or equal to 10(6.2) ID50 of human immunodeficiency virus (HIV), greater than or equal to 10(6) chimp infectious doses (CID50) of hepatitis B virus (HBV), and greater than or equal to 10(5) CID50 of hepatitis C virus (HCV). Immunization of rabbits with S/D-FFP and subsequent adsorption of elicited antibodies with untreated FFP confirmed the absence of neoimmungen formation. Coagulation factor content was comparable with that found in FFP. Based on these laboratory and animal studies, together with the extensive history of the successful use of S/D-treated coagulation factor concentrates, we conclude that replacement of FFP with S/D-FFP, prepared in a manufacturing facility, will result in improved virus safety and product uniformity with no loss of efficacy.


2013 ◽  
Vol 119 (4) ◽  
pp. 1050-1057 ◽  
Author(s):  
Marie Roguski ◽  
Kyle Wu ◽  
Ron I. Riesenburger ◽  
Julian K. Wu

Object A primary goal in the treatment of patients with warfarin-associated subdural hematoma (SDH) is reversal of coagulopathy with fresh-frozen plasma. Achieving the traditional target international normalized ratio (INR) of 1.3 is often difficult and may expose patients to risks of volume overload and of thromboembolic complications. This retrospective study evaluates the risk of mild elevations of INR from 1.31 to 1.69 at 24 hours after admission in patients presenting with warfarin-associated SDH. Methods Sixty-nine patients with warfarin-associated SDH and 197 patients with non–warfarin-associated SDH treated at a single institution between January 2005 and January 2012 were retrospectively identified. Charts were reviewed for patient age, history of trauma, associated injuries, neurological status at presentation, size and chronicity of SDH, associated midline shift, INR at admission and at hospital Day 1 (HD1), concomitant aspirin or Plavix use, platelet count, and medical comorbidities. Patients were stratified according to use of warfarin and by INR at HD1 (INR 0.8–1.3, 1.31–1.69, 1.7–1.99, and ≥ 2). The groups were evaluated for differences the in rate of radiographic expansion of SDH and in the rate of clinically significant SDH expansion resulting in death, unplanned procedure, and/or readmission. Results There was no difference in the rate of radiographic versus clinically significant expansion of SDH between patients not on warfarin and those on warfarin (no warfarin: 22.3% vs 20.3%, p = 0.866; warfarin: 10.7% vs 11.6%, p = 0.825), but the rate of medical complications was significantly higher in the warfarin subgroup (13.3% for patients who did not receive warfarin vs 26.1% for those who did; p = 0.023). For warfarin-associated SDH, there was no difference in the rate of radiographic versus clinically significant expansion between patients reversed to HD1 INRs of 0.8–1.3 and 1.31–1.69 (HD1 INR 0.8–1.3: 22.5% vs 20%, p = 1; HD1 INR 1.31–1.69: 15% vs 10%, p = 0.71). Conclusions Mild INR elevations of 1.31–1.69 in warfarin-associated SDH are not associated with a markedly increased risk of radiographic or clinically significant expansion of SDH. Larger prospective studies are needed to determine if subtherapeutic INR elevations at HD1 are associated with smaller increases in risk of SDH expansion.


2021 ◽  
Author(s):  
João Vitor Ribeiro dos Santos ◽  
Mariana Spitz ◽  
Ana Carolina Andorinho

Introduction: Thrombotic thrombocytopenic purpura (TTP) is a hematological disease resulting from the ADAMTS 13 plasmatic protein deficit. It can be congenital or sporadic, and is usually autoimmune. Pathological platelet adhesion occurs, leading to microthrombi in capillary and arterial circulation, microangiopathic anemia and ischemia. The clinical picture includes thrombocytopenia, renal dysfunction, fluctuating neurological symptoms, microangiopathic hemolytic anemia, and fever. Methods: Case report of a 51-year-old male hypertensive patient, diagnosed with idiopathic thrombocytopenic purpura (ITP) 10 years ago and submitted to splenectomy 5 years ago, who developed acute cholecystitis. He underwent urgent colecistectomy, and on the fourth postoperative day presented sudden space and time disorientation, transcortical motor aphasia and right faciobrachial paresis, with ipsilateral Babinski and Hoffman signs. Results: Brain CT showed left frontoparietal hypodensity. During hospitalization, there was worsening of renal function, increased LDH, and thrombocytopenia. Hematoscopy identified signs of intravascular hemolysis (erythrocyte fragmentation, reticulocytosis, helmet erythrocytes). Direct Coombs was negative. There was no history of heparin use. TTP was diagnosed, and fresh frozen plasma and prednisone 1mg/kg were prescribed. There was resolution of thrombotic microangiopathy, with subsequent increase of platelet levels, decreased LDH and improved hematoscopy. Conclusions: This case illustrates a rare cause of stroke and an unusual association of two hematological conditions: ITP and TTP. The treatment of TTP consists of replacement of deficient ADAMTS13 protein through plasmapheresis or fresh frozen plasma. The use of immunosuppressants is also associated, initially with glucocorticoids, followed by rituximab or splenectomy in order to prevent recurrences.


Author(s):  
Salim E. Abboud ◽  
Dean A. Nakamoto ◽  
John R. Haaga

The locally injected blood elements (LIBE) technique represents a useful alternative to systemic administration of blood products to reduce the risk of periprocedural hemorrhage in coagulopathic patients. The LIBE technique results in the creation of a “seroma” of platelets and/or blood products along the expected needle or instrument path to allow a high-quality blood clot to form, and it requires relatively less blood products compared to the more traditional systemic administration technique. Indications for LIBE include and expand on those for systemic administration of blood products to reverse pre-procedural coagulopathy, including contraindications to systemic reversal of pharmacologic anticoagulation, precarious fluid volume status, severe coagulopathy unlikely to normalize with systemic administration of blood products, patient history of adverse reaction to systemic administration of blood products, and limited availability of the desired blood product.


2019 ◽  
Vol 12 (11) ◽  
pp. e231457
Author(s):  
Mayank Jain ◽  
Ramesh Kekunnaya ◽  
Akshay Badakere

A young girl with constant exotropia was planned for surgery. Thorough preoperative workup was done and the patient underwent strabismus surgery. The girl developed preseptal haematoma on the third postoperative day with marked chemosis and oozing of blood from the conjunctival cul-de-sac. A history of factor XIII (FXIII) deficiency was later revealed by the caretakers. The patient was admitted and fresh frozen plasma was transfused for 5 days along with intravenous tranexamic acid. Orbital ultrasound and CT scan were done to confirm the location of the haematoma. The child improved significantly after 5 days and the proptosis subsided. FXIII deficiency is a rare form of bleeding disorder that is not revealed on routine coagulation profile tests. Fresh frozen plasma and recombinant FXIII are now available for treatment.


2013 ◽  
Vol 2013 ◽  
pp. 1-3 ◽  
Author(s):  
Nurettin Özgür Doğan ◽  
Gül Pamukçu Günaydın ◽  
Mustafa Tekin ◽  
Yunsur Çevik

Hemorrhagic complications due to warfarin use are frequently seen in emergency departments. However, nontraumatic massive hemothorax is an unexpected complication. We report a 59-year-old woman with warfarin overdose, who had massive hemothorax in right lung without any history of trauma. Her main complaint was significant dyspnea, which has gradually increased in three days. On her physical examination, she was tachypneic and had decreased lung sounds on her right hemithorax. She took warfarin regularly for aortic and mitral valve replacement for 18 years. Her INR level was 12.9 (0.8–1.2). Computed tomography of thorax revealed massive hemothorax with mediastinal shift. Fresh frozen plasma infusion was started immediately. Tube thoracostomy was performed for reexpansion of right lung and 2000 cc blood was drained in 5 minutes. Although hemorrhagic complications can be expected in warfarin therapy, thoracic hemorrhage related to warfarin therapy is relatively rare (3% of all hemorrhagic complications due to warfarin therapy). To our knowledge, massive hemothorax due to warfarin use is an extremely rare condition.


JMS SKIMS ◽  
2009 ◽  
Vol 12 (2) ◽  
pp. 53-55
Author(s):  
Javaid Rasool ◽  
Samoon Jeelani ◽  
Sajad Geelani ◽  
Abdul Rashid Lone ◽  
Afaq Ahmad ◽  
...  

Factor XIII deficiency is a rare disorder and these patients present with bleeding diathesis in the neonatal period. An 18 days old male child was brought with the history of umbilical stump bleeding. Two previous siblings had died in the neonatal period of an unknown cause, possibly because of intracranial haemorrhage and another at the age of 6 years of unknown cause. Investigations revealed Factor XIII deficiency. He was put on Fresh Frozen Plasma (FFP) support as he could not afford Fibrogammin and currently receives 6 weekly FFP and is doing well. J Med Sci 2009;12(2):53-55.


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4204-4204
Author(s):  
Fleur M Aung

Abstract 4204 A 58 year old male with a known clinical history of Passovoy defect was evaluated for a craniotomy for an olfactory meningioma. His family history revealed that this defect was present in multiple family members (siblings, parent and child). In the past, he had had several successful and several complicated surgeries. According to his past history, bleeding did not occur intra-operatively but typically 24-72 hours post-operatively. There was no evidence of mucosal bleeding, petechiae, rashes or ecchymosis on examination. There was no past history of spontaneous hemorrhage, epistaxis, hemoptysis, hematemesis, melena, petechiae or ecchymosis. Past surgical history revealed that when bleeding occurred and FFP was transfused post-operatively, the bleeding subsided. When Fresh Frozen Plasma (FFP) was transfused pre-operatively, intra-operatively and post-operatively there was no significant bleeding. Laboratory tests showed normal ProthrombinTime (PT), activated Partial Thromboplastin Time (aPTT), ThrombinTime (TT), Fibrinogen, Factor VIII and Factor XIII, vWFAntigen and vWF multimers. Platelet Aggregation studies were normal except for a decreased response to epinephrine. Thromboelastogram studies revealed a mild coagulation factor deficiency. Our workup did not show any of the common coagulation defects. There was no evidence of a prolonged Partial Thromboplastin Time (aPTT) as reported in the literature. Due to normal aPTT results (average 27.7 secs, range 25.5– 38.1 secs), mixing studies were not performed. Due to his significant past clinical history, the patient was transfused with Fresh Frozen Plasma (FFP) pre-operatively, intra-operatively and post- operatively for 72 hrs. The PT/aPTT and platelet counts remained within normal range throughout the patient's entire hospital stay with no evidence of bleeding post-operatively. Passovoy Defect is a rare autosomal disorder and is a coagulation abnormality affecting the intrinsic coagulation system characterized by a prolonged aPTT. The defect is associated with a clinical bleeding tendency characterized by easy bruising and undue blood loss following trauma and/or surgery. Fresh Frozen Plasma appears to provide effective prophylaxis during surgery. The bleeding phenotype is variable. There may be no bleeding after major surgeries. Major bleeding after minor surgeries is not uncommon. Our case represents a rare type of a defect in the intrinsic system that may not be encountered in the daily setting with a normal active Partial Thromboplastic Time (aPTT). The Passovoy Defect in our patient appears to be transmitted as an autosomal dominant trait. Despite a very significant clinical and family history, the aPTT was within normal range throughout his hospitaization. No diagnostic laboratory findings were noted. It has been reported that the prolongation of aPTT in some of the patients may be relatively mild. However this was not the case in our patient. We do not know whether our patient has a deficiency of an unknown coagulation factor or that our aPTT reagent (HemosIL SynthASIL Catalogue # 20006800, DiaPharma Group Inc, West Chester, OH, USA) was not sensitive to the Passovoy Defect. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
1992 ◽  
Vol 79 (3) ◽  
pp. 826-831 ◽  
Author(s):  
B Horowitz ◽  
R Bonomo ◽  
AM Prince ◽  
SN Chin ◽  
B Brotman ◽  
...  

Fresh frozen plasma (FFP) is prepared in blood banks world-wide as a by- product of red blood cell concentrate preparation. Appropriate clinical use is for coagulation factor disorders where appropriate concentrates are unavailable and when multiple coagulation factor deficits occur such as in surgery. Viral safety depends on donor selection and screening; thus, there continues to be a small but defined risk of viral transmission comparable with that exhibited by whole blood. We have prepared a virus sterilized FFP (S/D-FFP) by treatment of FFP with 1% tri(n-butyl)phosphate (TNBP) and 1% Triton X-100 at 30 degrees C for 4 hours. Added reagents are removed by extraction with soybean oil and chromatography on insolubilized C18 resin. Treatment results in the rapid and complete inactivation of greater than or equal to 10(7.5) infectious doses (ID50) of vesicular stomatitis virus (VSV) and greater than or equal to 10(6.9) ID50 of sindbis virus (used as marker viruses), greater than or equal to 10(6.2) ID50 of human immunodeficiency virus (HIV), greater than or equal to 10(6) chimp infectious doses (CID50) of hepatitis B virus (HBV), and greater than or equal to 10(5) CID50 of hepatitis C virus (HCV). Immunization of rabbits with S/D-FFP and subsequent adsorption of elicited antibodies with untreated FFP confirmed the absence of neoimmungen formation. Coagulation factor content was comparable with that found in FFP. Based on these laboratory and animal studies, together with the extensive history of the successful use of S/D-treated coagulation factor concentrates, we conclude that replacement of FFP with S/D-FFP, prepared in a manufacturing facility, will result in improved virus safety and product uniformity with no loss of efficacy.


Sign in / Sign up

Export Citation Format

Share Document